ALEC

Alector Inc

ALEC.US alector.com + Research + Basket
CIK 0001653087
Employees 103
Phone 415 231 5660
Fiscal year end December
IPO Feb 07, 2019
Address 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
2.09
-0.19 (-8.33%)
USD · NASDAQ
52-week range
1.09
2.76
Trading at 60% of the 52-week range
Market Cap
254.58M
P/E Ratio
0.00
Forward P/E
8.47
Book Value
-0.09
Div. Yield
N/A
% Institutions
84.06%
% Insiders
7.38%

1 Year

+66.5%

3 Year

-61.8%

10 Year

-88.4%
Description

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Actions

Add an action for ALEC.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Arnon Rosenthal Ph.D. Co-Founder, CEO & Director 1956
Mr. Neil Berkley M.B.A., M.S. CFO & Chief Business Officer 1974
Ms. Grace Wong-Sarad Chief Accounting Officer & Principal Accounting Officer NA
Ms. Katie Hogan Senior Director of Corporate Communication & Investor Relations NA
Ms. Danielle Pasqualone J.D., Ph.D. General Counsel NA
Ms. Clare Hunt M.B.A. Chief People & Places Officer NA
Dr. Hua Long DABT, Ph.D. Senior VP & Head of Research NA
Dr. Caiyan Li Ph.D. Head of Clinical Development & Data Science NA
Dr. Eric Brown Ph.D. Director of Antibody Discovery & Protein Engineering NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 16, 2026 Grace Wong-Sarad N/A Sale 1.82K $2.65 $4.82K SEC
Mar 10, 2026 Grace Wong-Sarad N/A Sale 1.00K $2.65 $2.65K SEC
Feb 26, 2026 Grace Wong-Sarad N/A Sale 4.08K $2.50 $10.20K SEC
Dec 05, 2025 Grace Wong-Sarad N/A Sale 4.75K $1.21 $5.75K SEC
Dec 03, 2025 Arnon Rosenthal N/A Sale 104.35K $1.12 $116.87K SEC
Dec 03, 2025 Grace Wong-Sarad N/A Sale 8.06K $1.12 $9.02K SEC
Dec 03, 2025 Neil Lindsay Berkley N/A Sale 37.26K $1.12 $41.73K SEC
Dec 03, 2025 Sara Kenkare-Mitra N/A Sale 41.69K $1.12 $46.69K SEC
Sep 02, 2025 Grace Wong-Sarad N/A Sale 5.91K $2.50 $14.78K SEC
Aug 26, 2025 Paula Hammond N/A Sale 14.00K $2.36 $33.04K SEC
Jun 20, 2025 Kristine Yaffe N/A Sale 1.00K $1.44 $1.44K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
TCG Crossover Management, LLC 10.00M Jun 30, 2026 8.96% $0.48 0.00%
Nantahala Capital Management, LLC 8.64M Jun 30, 2026 7.73% $0.29 206.69%
BlackRock Inc 7.85M Jun 30, 2026 7.03% $0.00 1.38%
Acadian Asset Management LLC 4.41M Jun 30, 2026 3.95% $0.01 9.30%
Vanguard Capital Management, LLC 4.01M Jun 30, 2026 3.59% $0.00 8.99%
Kynam Capital Management, LP 3.81M Jun 30, 2026 3.41% $0.42 90.42%
Merck & Co Inc 3.55M Jun 30, 2026 3.18% $1.35 0.00%
Balyasny Asset Management LLC 3.25M Jun 30, 2026 2.91% $0.01 10.64%
D. E. Shaw & Co LP 2.96M Jun 30, 2026 2.65% $0.00 -11.19%
ADAR1 Capital Management LLC 2.88M Jun 30, 2026 2.58% $0.27 174.63%
Vanguard Portfolio Management, LLC 2.82M Jun 30, 2026 2.53% $0.00 9.17%
Geode Capital Management, LLC 2.45M Jun 30, 2026 2.20% $0.00 7.35%
Spruce Street Capital LP 2.10M Jun 30, 2026 1.88% $0.83 0.00%
Millennium Management LLC 1.99M Jun 30, 2026 1.78% $0.00 0.49%
Ikarian Capital, LLC 1.98M Jun 30, 2026 1.78% $0.43 -4.80%
State Street Corp 1.88M Jun 30, 2026 1.68% $0.00 0.76%
Jacobs Levy Equity Management, Inc. 1.77M Jun 30, 2026 1.58% $0.01 -18.03%
Medici Capital LLC 1.65M Jun 30, 2026 1.48% $6.51 0.00%
Affinity Asset Advisors, LLC 1.51M Jun 30, 2026 1.35% $0.14 202.00%
Eversept Partners, LP 1.42M Jun 30, 2026 1.28% $0.15 5.39%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 2.84M 2.54% ▲ 0.00% Sep 30, 2026
2 iShares Russell 2000 ETF 2.49M 2.23% ▼ 0.41% Oct 29, 2026
3 Fidelity Small Cap Index 1.07M 0.96% ▼ 0.12% Jul 31, 2026
4 iShares Russell 2000 Growth ETF 833.50K 0.75% ▲ 0.25% Oct 29, 2026
5 Vanguard Explorer Inv 673.49K 0.60% ▲ 0.00% Sep 30, 2026
6 Vanguard Strategic Small-Cap Equity Inv 628.63K 0.56% ▲ 0.00% Sep 30, 2026
7 Vanguard Russell 2000 ETF 538.79K 0.48% ▼ 4.38% Sep 30, 2026
8 Schwab US Small-Cap ETF™ 504.31K 0.45% ▲ 0.00% Oct 30, 2026
9 Vanguard VIF Small Co Gr 494.84K 0.44% ▼ 19.66% Sep 30, 2026
10 Fidelity Extended Market Index 359.70K 0.32% ▼ 0.53% Aug 31, 2026

Financial Highlights

▼
Market Cap: $254.58M
EBITDA: $-119.03M
Book Value: $-0.09
Earnings/Share: $-1.09
Profit Margin: 0.00%
Operating Margin: -734.73%
ROA (TTM): -27.62%
ROE (TTM): -385.11%
Revenue (TTM): $13.86M
Revenue/Share (TTM): $0.13
Earnings Growth (YOY): -86.30%
Revenue Growth (YOY): -57.80%

Valuation Metrics

Enterprise Value: $100.02M
Trailing P/E: 0.00
Forward P/E: 8.47

Shares Statistics

Shares Outstanding: 111.66M
Shares Float: 76.28M
% Insiders: 7.38%
% Institutions: 84.06%
Shares Short: 10.25M
Shares Short (Prior Month): 6.15M
Short Ratio: 1.72
Short % Float: 9.73%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$21.05M
Cost of Goods Sold
adjust
$-9.66M
Gross Profit
subtotal
$11.38M
SG&A
adjust
$-53.99M
R&D
adjust
$-123.07M
Operating Income
subtotal
$-145.81M
Other / Non-Operating Items
adjust
$2.88M
Net Income
subtotal
$-142.93M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ALEC.US!